Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.

Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.

Combining immune intervention with therapies that directly influence the functional state of the β-cells is an interesting strategy in type 1 diabetes cure. Dipeptidyl peptidase-4 (DPP-4) inhibitors elevate circulating levels of active incretins, which have been reported to enhance insulin secretion...

Full description

Bibliographic Details
Main Authors: Lei Ding, Conny A Gysemans, Geert Stangé, Yves Heremans, Yixing Yuchi, Tatiana Takiishi, Hannelie Korf, Marie Chintinne, Richard D Carr, Harry Heimberg, Daniel Pipeleers, Chantal Mathieu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4182446?pdf=render

Internet

http://europepmc.org/articles/PMC4182446?pdf=render

Similar Items